A liposomal nanoparticle platform technology for the delivery oftaxanes - A case study

3^rd International Conference and Exhibition on Materials Science & Engineering

October 06-08, 2014 Hilton San Antonio Airport, USA

Charan R Behl, Indu Javeri and Nellaiappan Kaliappanadar

Accepted Abstracts: Material Sci Eng

Abstract :

The development of novel therapeutic candidates as well as some approved compounds faces the critical challenge of limited aqueous solubility, which results in reduced efficacy. Formulation strategies employed to deliver such compounds typically rely on the use of less desirable excipients such as ethanol, DMSO, cremophore, detergents etc. While these excipients improve solubility, they are toxic, often precipitates upon dilution in vivo or in vitro reducing the bioavailability. In many cases their use may result in undesirable side effects or sensitivities which reduce the therapeutic window and often require specific pre-treatment with other drugs. These formulations also require complicated steps and therefore more expensive manufacturing processes. Currently many liposomal and polymers nanoparticles are under investigation for drug deliver to overcome and solve the limitations of conventional drug delivery systems such as nonspecific bio-distribution, lack of aqueous solubility, poor oral bioavailability, and low therapeutic indices. The particle size and surface characteristics have been optimized to increase their circulation time in the bloodstream and to improve the safety, pharmacokinetics, and bio-distribution of drugs. Scientists at CuriRx, Inc. have developed a novel, liposomal nanoparticle platform technology for the delivery of such therapeutic compounds with not only better safety, efficacy, pharmacokinetics/pharmacodynamics profiles but also with easy scalable manufacturing process. A case study of development efforts of docetaxel encapsulated in the liposomal nanoparticle having significant clinical and manufacturing advantages over Taxotere: increased efficacy, improved pharmacokinetics, reduced toxicity, excellent stability, and enhanced solubility, will be presented.

Biography :

Charan R Behl, PhD, is a consultant to CuriRx, Inc. and he is also engaged in the development of drug products including oral controlled release, transdermal, dermatological, parenteral, nasal, and ophthalmic drug products. He previously held executive positions at Elite Pharma, Northvale, NJ, and Nastec h Pharma, Hauppauge, NY; and senior positions at Roche, NJ. He got his PhD in Pharmaceutical Sciences from the University of Michigan, Ann Arbor, MI; MS in Pharmaceutical Chemistry from Duquesne University, Pittsburg, PA; and BPharm (Hons) from BITS, Pilani, India. He has, over the past 30+ years worked in the research and development of ?challenging drugs?. He has over 200 research articles, book chapters, and abstracts at major conferences; over 40 patents granted, under review, and in-preparation. He has co-organized many symposia working closely with colleagues from the academia, industry, the NIH, and the FDA. He is also a Fellow of the American Association of Pharmaceuticals Scientists (AAPS).